MX2018002304A - Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono. - Google Patents

Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.

Info

Publication number
MX2018002304A
MX2018002304A MX2018002304A MX2018002304A MX2018002304A MX 2018002304 A MX2018002304 A MX 2018002304A MX 2018002304 A MX2018002304 A MX 2018002304A MX 2018002304 A MX2018002304 A MX 2018002304A MX 2018002304 A MX2018002304 A MX 2018002304A
Authority
MX
Mexico
Prior art keywords
citrate
stimulating
carbohydrate metabolism
mineral compositions
metabolism
Prior art date
Application number
MX2018002304A
Other languages
English (en)
Inventor
Werner Tanja
Original Assignee
Protina Pharmazeutische Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protina Pharmazeutische Gmbh filed Critical Protina Pharmazeutische Gmbh
Publication of MX2018002304A publication Critical patent/MX2018002304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En esta memoria se describen nuevos aplicaciones de mezclas a base de tres o más sales citrato, que comprenden citrato de magnesio, comprendiendo la mezcla a base de tres o más sales citrato adicionalmente citrato de calcio y/o citrato de zinc, en particular para estimular o potenciar el metabolismo de los hidratos de carbono, preferiblemente el metabolismo de la glucosa, en particular para estimular o potenciar el metabolismo energético celular.
MX2018002304A 2015-08-25 2016-08-17 Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono. MX2018002304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15182351.5A EP3135273B1 (de) 2015-08-25 2015-08-25 Mineralstoffzusammensetzungen zur anregung des kohlenhydratstoffwechsels
PCT/EP2016/069522 WO2017032665A1 (de) 2015-08-25 2016-08-17 Mineralstoffzusammensetzungen zur anregung des kohlenhydratstoffwechsels

Publications (1)

Publication Number Publication Date
MX2018002304A true MX2018002304A (es) 2018-08-01

Family

ID=54011600

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002304A MX2018002304A (es) 2015-08-25 2016-08-17 Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.

Country Status (5)

Country Link
EP (1) EP3135273B1 (es)
AU (1) AU2016311131B2 (es)
MX (1) MX2018002304A (es)
RU (1) RU2018110274A (es)
WO (1) WO2017032665A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017011958A1 (de) * 2017-12-22 2019-06-27 Marco Loh Zubereitung zur Mineralisierung von Trinkwasser
WO2019201707A1 (de) * 2018-04-19 2019-10-24 Prosalix Ag Stoffgemisch umfassend k-mg-citrat zur verwendung als arzneimittel
WO2019225722A1 (ja) * 2018-05-25 2019-11-28 国立大学法人 琉球大学 代謝改善剤
DE102019128196A1 (de) 2019-10-18 2021-04-22 Prosalix Ag Präparat zur medizinischen Verwendung für die Behandlung einer Krankheit infolge Schädigung der tubulären Nierenfunktion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963034A1 (de) 1999-12-24 2001-06-28 Roche Diagnostics Gmbh System zur verbesserten Bestimmung des Glukosespiegels anhand von Messungen in interstitieller Flüssigkeit
US20030004215A1 (en) * 2001-06-15 2003-01-02 Van Laere Katrien Maria Jozefa Dietetic preparation and method for inhibiting intestinal carbohydrate absorption
US20030099626A1 (en) * 2001-11-20 2003-05-29 Health Education Corporation Nutrient absorption enhancing compositions and methods
DE10160485A1 (de) * 2001-12-08 2003-10-02 Degussa Verwendung von Kreatin und/oder einem seiner physiologisch geeigneten Derivate zur Prävention oder Linderung von nicht krankheitsbedingten Beeinträchtigungen und/oder Störungen der Muskelfunktion
FR2883132B1 (fr) * 2005-03-15 2009-02-13 Larena Sa Composition alimentaire suppletive
US10251909B2 (en) * 2007-02-09 2019-04-09 Board Of Regents, The University Of Texas System Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension
US8178133B2 (en) * 2007-03-22 2012-05-15 Magceutics, Inc. Magnesium compositions and uses thereof
EP2072046A1 (de) * 2007-12-21 2009-06-24 K.F. Prof. Dr. Kopp Verwendung einer hydrocarbonathaltigen Zubereitung zur Prävention oder Behandlung von Herz-Kreislauf-Erkrankungen, Diabetes, Osteoporose und chronischem Nierenversagen
IT1406068B1 (it) * 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego

Also Published As

Publication number Publication date
WO2017032665A1 (de) 2017-03-02
RU2018110274A (ru) 2019-09-26
RU2018110274A3 (es) 2019-10-29
NZ740091A (en) 2021-11-26
EP3135273A1 (de) 2017-03-01
AU2016311131A1 (en) 2018-03-15
EP3135273B1 (de) 2020-07-15
AU2016311131B2 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12017502002A1 (en) 5`-substituted nucleoside analogs
MY188363A (en) Substituted tricyclic compounds as fgfr inhibitors
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
BR112014031421A2 (pt) composições para tratamento de câncer e métodos para produção das mesmas
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
MY179243A (en) Supplemented fish feed
MX2019010039A (es) Composiciones y métodos para transducción de tumores.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2018002304A (es) Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.
MX2021001441A (es) Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.
MX2015008877A (es) Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos.
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2017013772A (es) Conjugados mezclados de disulfuro de compuestos de tienopiridina y usos de los mismos.
MX2019000677A (es) Células miméticas de células b.
MX2015001648A (es) Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.
MX368972B (es) Composiciones de glicoproteínas sialiladas y usos de estas.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
MY182809A (en) Compositions for the treatment of kidney and/or liver disease